テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma |
掲載誌名 | 正式名:Jpn J Clin Oncol ISSNコード:14653621 |
掲載区分 | 国外 |
巻・号・頁 | 50,1265-1273頁 |
著者・共著者 | Maruyama, D., Terui, Y., Yamamoto, K., Fukuhara, N., Choi, I., Kuroda, J., Ando, K., Hattori, A., Tobinai, K. |
発行年月 | 2020 |
概要 | In Japanese patients with relapsed or refractory classical Hodgkin lymphoma.|Japanese patients with previously treated classical Hodgkin lymphoma (aged ≥ 20 years) were administered nivolumab (3 mg/kg on Day 1 of 14-day cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason.The centrally assessed overall response rate in 16 classical Hodgkin lymphoma patients was 87.5% . The median duration of response and progression-free survival were 8.5 (2.4-12.6) and 11.7 (1.8-42.3) months, respectively. The 3-year overall survival rate was 80.4%. Nivolumab was continued beyond progressive disease in seven patients; six were alive at the data cut-off. Adverse drug reactions occurred in all 17 patients with grades 3-4 adverse drug reactions in eight patients and no grade 5 adverse drug reactions. Pulmonary toxicities occurred in five patients; four of these occurred ≥17 months after starting nivolumab. |
DOI | 10.1093/jjco/hyaa117 |
文献番号 | 32776097 |